BlossomHill Therapeutics, Inc. (BLSM)

BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?

BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise